TFRC and neoplasm: The designed Tf@IR820‐DHA nanoparticles could not only specifically target tumor tissues with high expression level of the transferrin receptor (TfR1), but also combine CDT with SDT to promote the generation of ROS and cause a high level of targeted ICDs (Figure7a).[111] Studies have demonstrated that DHA is not only an anticancer drug that produces ROS, but also an efficient ICD inducer.[112, 113] The results showed that the combination of IR820‐mediated SDT and DHA‐mediated CDT had the best therapeutic efficiency compared to other treatment groups (Figure 7b).